Innate Pharma Files 6-K, Reports Press Release
Ticker: IPHYF · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on 3/20/25, likely with news in the attached press release.
AI Summary
Innate Pharma SA filed a Form 6-K on March 20, 2025, reporting a press release dated March 20, 2025. The filing does not contain specific financial figures or operational details beyond the reporting of this press release.
Why It Matters
This filing indicates Innate Pharma is providing updated information to the SEC, likely related to recent business developments or announcements detailed in the press release.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, without disclosing new material financial or operational risks.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- March 20, 2025 (date) — Filing and Press Release Date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated March 20, 2025, as required for foreign private issuers.
What is the filing date of this Form 6-K?
This Form 6-K was filed on March 20, 2025.
Does this filing include an annual report on Form 20-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F, marked with a checkmark, but this specific filing is a 6-K.
What is the principal executive office address for Innate Pharma S.A.?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 99.1 is included, which is a Press Release dated March 20, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding Innate Pharma SA (IPHYF).